Year: 2025
Type: article
Abstract: The Involvement row lists measurable sites of HCL/HCLv outside the bone marrow, which also constituted indications for treatment.Mutations were determined by TSO500 NGS of 523 genes.VAF are listed in parentheses after each mutation.The number of doses per course was usually 5-7 for cladribine (CDA), 6-12 for pentostatin (DCF), and 4-8 for rituximab (R).
Source: JCO Precision Oncology
DOI: 10.1200/po-25-00269
Authors: Robert J. Kreitman, Brett Schroeder, Evgeny Arons, Constance Yuan, Hao-Wei Wang, Mark Raffeld, Liqiang Xi, Stefania Pittaluga, Hong Zhou, Mory Gould, Isaac Shpilman, Evrim Turkbey, Katherine R. Calvo, Lacey James, Olena Sierra Ortiz, Steve Highfill, David Stroncek, Bonnie Yates, Ira Pastan, Nirali N. Shah
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
OpenAlex ID: W4412484745